Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania

Pharmacological Reports

Volumn 63, Issue 1, 2011, Pages 64-70

  Barbosa, Francisco J ^a   Hesse, Bernardete ^a   De Almeida, Rodrigo B ^a   Baretta, Irinéia P ^a,b   Boerngen Lacerda, Roseli ^a   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSIDADE PARANAENSE   (Brazil)

Author keywords

Anticonvulsant; Locomotor activity; Magnesium sulfate; Mania; Psychostimulant; Valproate

Indexed keywords

MAGNESIUM SULFATE; METHYLPHENIDATE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; HYPERACTIVITY; MALE; MANIA; MOUSE; NONHUMAN; OPEN FIELD TEST; RETREATMENT;

EID: 79953229270     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70399-1     Document Type: Article

References (33)

1. Arban R, Maraia G, Brackenborough K, Winyard L, Wilson A, Gerrard P, Large C: Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res, 2005, 158, 123-132. (Pubitemid 40174717)
2. Barbier E, Wang JB: Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level. BMC Neurosci, 2009, 10, 132.
3. Barros HM, Leite JR: The effects of carbamazepine on two animal models of depression. Psychopharmacology (Berl), 1987, 92, 340-342. (Pubitemid 17100483)
4. Beijamini V, Skalisz LL, Joca SR, Andreatini R: The effect of oxcarbazepine on behavioural despair and learned helplessness. Eur J Pharmacol, 1998, 347, 23-27. (Pubitemid 28238082)
5. Bowden CL: Pharmacological treatment of bipolar disorder: a review. In: Bipolar Disorder (WPA series: Evidence and Experience in Psychiatry, vol. 5). Ed. Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N, John Wiley & Sons, Chichester, 2002, 191-277.
6. Cardoso CC, Lobato KR, Binfare RW, Ferreira PK, Rosa AO, Santos AR, Rodrigues AL: Evidence for the involvement of the monoaminergic system in the antidepressant- like effect of magnesium. Prog Neuropsychopharmacol Biol Psychiatry, 2009, 33, 235-242.
7. Chouinard G, Beauclair L, Geiser R, Etienne P: A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Prog Neuropsychopharmacol Biol Psychiatry, 1990, 14, 171-180. (Pubitemid 20078459)
8. Consoni FT, Vital MA, Andreatini R: Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. Eur Neuropsychopharmacol, 2006, 16, 451-458. (Pubitemid 43996884)
9. Decollogne S, Tomas A, Lecerf C, Adamowicz E, Seman M: NMDA receptor complex blockade by oral administration of magnesium: comparison with MK-801. Pharmacol Biochem Behav, 1997, 58, 261-268. (Pubitemid 27334381)
10. Donzanti BA, Uretsky NJ: Magnesium selectively inhibits N-methyl-aspartic acid-induced hypermotility after intra-accumbens injection. Pharmacol Biochem Behav, 1984, 20, 243-246. (Pubitemid 14167971)
11. Eckermann K, Beasley A, Yang P, Gaytan O, Swann A, Dafny N: Methylphenidate sensitization is modulated by valproate. Life Sci, 2001, 69, 47-57. (Pubitemid 32523933)
12. Einat H: Modeling facets of mania: new directions related to the notion of endophenotypes. J Psychopharmacol, 2006, 20, 714-722.
13. Einat H, Yuan P, Szabo ST, Dogra S, Manji HK: Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology, 2007, 55, 123-131. (Pubitemid 47525230)
14. Euser AG, Cipolla MJ: Magnesium sulfate for the treatment of eclampsia: a brief review. Stroke, 2009, 40, 1169-1175.
15. Frey BN, Andreazza AC, Ceresér KM, Martins MR, Valvassori SS, Réus GZ, Quevedo J, Kapczinski F: Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci, 2006, 79, 281-286. (Pubitemid 43782552)
16. Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M: Magnesium oxide augmentation of verapamil maintenance therapy in mania. Psychiatry Res, 2000, 93, 83-87. (Pubitemid 30123138)
17. Gould TJ, Keith RA, Bhat RV: Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav Brain Res, 2001, 118, 95-105. (Pubitemid 32037118)
18. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S: Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Res, 1999, 89, 239-246. (Pubitemid 30053006)
19. Izenwasser SE, Garcia-Valdez K, Kantak KM: Stimulant-like effects of magnesium on aggression in mice. Pharmacol Biochem Behav, 1986, 25, 1195-1199. (Pubitemid 17212800)
20. Kantak KM, Adlerstein LK: Enhancement of apomorphine and l-amphetamine-induced behaviors by magnesium. Pharmacol Biochem Behav, 1990, 36, 29-33. (Pubitemid 20165630)
21. Murck H: Magnesium and affective disorders. Nutr Neurosci, 2002, 5, 375-389.
22. Nechifor M: Interactions between magnesium and psychotropic drugs. Magnes Res, 2008, 21, 97-100.
23. Poleszak E, Szewczyk B, Kedzierska E, Wlaź P, Pilc A, Nowak G: Antidepressant-and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav, 2004, 78, 7-12. (Pubitemid 38670508)
24. Poleszak E, Szewczyk B, Wlaź A, Fidecka S, Wlaź P, Pilc A, Nowak G: D-serine, a selective glycine/N-methyl- D-aspartate receptor agonist, antagonizes the antidepressant- like effects of magnesium and zinc in mice. Pharmacol Rep, 2008, 60, 996-1000.
25. Poleszak E, Wlaź P, Kedzierska E, Nieoczym D, Wróbel A, Fidecka S, Pilc A, Nowak G: NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav, 2007, 88, 158-164. (Pubitemid 350115999)
26. Poleszak E, Wlaź P, Kedzierska E, Nieoczym D, Wyska E, Szymura-Oleksiak J, Fidecka S et al.: Immobility stress induces depression-like behavior in the forced swim test in mice: effect of magnesium and imipramine. Pharmacol Rep, 2006, 58, 746-752. (Pubitemid 44741694)
27. Poleszak E, Wlaź P, Kedzierska E, Radziwoń-Zaleska M, Pilc A, Fidecka S, Nowak G: Effects of acute and chronic treatment with magnesium in the forced swim test in rats. Pharmacol Rep, 2005, 57, 654-658.
28. Sabioni P, Baretta IP, Ninomiya EM, Gustafson L, Rodrigues AL, Andreatini R: The antimanic-like effect of tamoxifen: behavioural comparison with other PKC-inhibiting and antiestrogenic drugs. Prog Neuropsychopharmacol Biol Psychiatry, 2008, 32, 1927-1931.
29. Szabo ST, Machado-Vieira R, Yuan P, Wang Y, Wei Y, Falke C, Cirelli C et al.: Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology, 2009, 56, 47-55.
30. Szewczyk B, Poleszak E, Sowa-Kućma M, Siwek M, Dudek D, Ryszewska-Pokraoeniewicz B, Radziwoń-Zaleska M et al.: Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep, 2008, 60, 588-599.
31. Yang P, Singhal N, Modi G, Swann A, Dafny N: Effects of lithium chloride on induction and expression of methylphenidate sensitization. Eur J Pharmacol, 2001, 426, 65-72. (Pubitemid 32781789)
32. Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF: Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry, 2008, 65, 255-263. (Pubitemid 351342442)
33. Zarate CA, Manji HK: Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs, 2009, 23, 569-582.